Zenas BioPharma Revenue

Zenas BioPharma had revenue of $15.00M in the twelve months ending September 30, 2025. In the year 2024, Zenas BioPharma had annual revenue of $5.00M, down -90.00%.

Revenue (ttm)

$15.00M

Revenue Growth

-90.00%

P/S Ratio

109.32

Revenue / Employee

$115,385

Employees

130

Market Cap

2.10B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	5.00M	-45.00M	-90.00%
Dec 31, 2023	50.00M	-	-
Dec 31, 2022	-	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

ZBIO News

4 weeks ago - Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
4 weeks ago - Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
6 weeks ago - Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis - GlobeNewsWire
7 weeks ago - Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948 - The Motley Fool
2 months ago - Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal - Seeking Alpha
2 months ago - Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters
2 months ago - Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - GlobeNewsWire
3 months ago - Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - GlobeNewsWire

More News